Vancouver biotech NanoVation Therapeutics has announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. With the partnership, NanoVation will receive research funding and is eligible to receive up to approximately USD $600 million in up-front cash and potential milestone payments, as well as tiered […]